Management of Fibroblast Growth Factor Inhibitor Treatment–emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma-Reference-Cited by-同舟云学术

Management of Fibroblast Growth Factor Inhibitor Treatment–emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Published:2023-04 Issue: Volume:50 Page:1-9
ISSN:2666-1683
Container-title:European Urology Open Science
language:en
Short-container-title:European Urology Open Science

Author:

Siefker-Radtke Arlene O.,Necchi Andrea,Park Se Hoon,García-Donas Jesús,Huddart Robert A.,Burgess Earle F.,Fleming Mark T.,Rezazadeh Kalebasty Arash,Mellado Begoña,Varlamov Sergei,Joshi Monika,Duran Ignacio,Tagawa Scott T.,Zakharia Yousef,Qi Keqin,Akapame Sydney,Triantos Spyros,O'Hagan Anne,Loriot Yohann

Publisher

Elsevier BV

Subject

Urology

Reference22 articles.

1. Erdafitinib for the treatment of urothelial cancer;Marandino;Expert Rev Anticancer Ther,2019

2. BALVERSA® (prescribing information). Horsham, PA: Janssen Products, LP; 2020.

3. Erdafitinib in locally advanced or metastatic urothelial carcinoma;Loriot;N Engl J Med,2019

4. Facts and new hopes on selective FGFR inhibitors in solid tumors;Facchinetti;Clin Cancer Res,2020

5. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study;Schuler;Lancet Oncol,2019

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia;Journal of Medicinal Chemistry;2024-09-11

2. The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies;Critical Reviews in Oncology/Hematology;2024-08

3. The Role of Fibroblast Growth Factor Receptors Inhibitors in Bladder Cancer;Journal of Urologic Oncology;2024-07-31

4. A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants;Cancer Research;2024-07-02

5. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions;Nature Reviews Clinical Oncology;2024-02-29